Cord Blood America CEO to Present Detailed Stock Comparison of Stem Cell Companies at SCIA Conference.

LOS ANGELES -- Cord Blood America, Inc. (OTCBB:CBAI), the umbilical cord blood stem cell preservation company which is focused on bringing the life saving potential of stem cells to families nationwide, in an upcoming presentation to the Southern California Investment Association, will compare the Company to others in its sector based on established financial guidelines and highlight Cord Blood America's advantages.

The presentation will be held on Saturday, April 1, 2006, between 8 and 8:30 a.m at the Orange County Airport Hilton.

"In the presentation, we will compare our Company to other small cap stem cell companies on key financial parameters and demonstrate to the participants at the SCIA conference how well Cord Blood America ranks in this comparison," said Matthew Schissler, Chairman and CEO.

"Our analysis shows that of the stem cell companies we've tracked, Cord Blood America ranks in the top half, or better in total revenues, percentage of quarterly revenue growth, revenues per share, EBITDA and earnings per share. Yet we rank near the bottom in terms of share price and we have one of the lowest market caps out of these companies," Mr. Schissler said.

"We believe there are several reasons for the current state of our stock price", Mr. Schissler said, "and all are important for our shareholders and potential shareholders to consider. At the upcoming SCIA conference, I will analyze and detail the stem cell sector and highlight our growth strategy to reflect the current valuations in the market place."

Mr. Schissler will explain in greater detail why he feels CBAI is currently an undervalued stock. "We have a large and growing market, a pricing advantage over competitors, we exhibit the rapid growth characteristics that Wall Street demands, have an aggressive growth strategy, and we are a marketing leader in this arena. We urge investors to take a look at our presentation and then reevaluate their investment in this sector. Our commitment to increasing shareholder value is total and complete."

Other public companies compared in the upcoming presentation have market caps of approximately $700 million or under and include: Geron Corporation (NASDAQ:GERN), ViaCell (NASDAQ:VIAC), Cryo-Cell International, Inc. (OTCBB:CCEL), and Bio-Stem, Inc. (OTCBB:BTEM), among others.

About Cord Blood America

Cord Blood America, Inc. (OTC Bulletin Board:CBAI) is the parent company of Cord Partners, which facilitates umbilical cord blood stem cell preservation for expectant parents and their children. Stem cells have proven successful in replacing other cells that are damaged or missing due to a disease. Unlike embryonic stem cells, there is no controversy with the collection or use of these stem cells. Cord Blood America facilitates the harvest of stem cells from umbilical cords that traditionally have been discarded at birth for the sole use of the family.

For more information on how this precious lifeline can benefit your family, visit http://www.cordpartners.com . To find out more about Cord Blood America, Inc. (OTCBB:CBAI), visit our website at www.cordblood-america.com.

Forward-Looking Statements

Some statements made in this press release are forward-looking statements, which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. We use words such as "anticipate," "believe," "expect," "future," "intend," "plan," and similar expressions to identify forward-looking statements. These statements including those related to CBAI being an undervalued stock, being in a large and growing market, exhibiting rapid growth characteristics, and having a growth strategy, are forward looking statements. These forward looking statements are only predictions and are subject to certain risks, uncertainties and assumptions. Some of the risks, uncertainties and assumptions that could cause actual results to differ materially from estimates or assumptions in this press release include the risk that our stock price will not increase, the risk that we will not be able to grow our revenues and market share, the risk that our prices do not remain competitive and the risk that we will not achieve profitability. Additional risks are identified and described in the Company's public filings with the Securities and Exchange Commission, including our most recent Report on From 10-KSB and subsequent Reports on Form 10-QSB and Form 8-K. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company's past performance is not necessarily indicative of its future performance. The Company does not undertake, and the Company specifically disclaims any obligation to update any forward-looking statements to reflect occurrences, developments, events, or circumstances after the date of such statement.